Myasthenia Gravis Treatment Market Trends 2024 : Rise in Demand for Effective Treatments for Myasthenia Gravis is Boosting USD 3.1 Billion Revenue of the Market by 2032

According to a new report published by Allied Market Research, titled, "Myasthenia Gravis Treatment Market," The myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is estimated to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

The growth of the myasthenia gravis treatment market is fueled by several factors, including a growing demand for more efficient treatments, advancements in medical research and development, and heightened awareness regarding early diagnosis and available treatment choices. With the prevalence of myasthenia gravis on the rise, there's an increasing need for effective treatments. Individuals with myasthenia gravis often grapple with muscle weakness and fatigue, significantly impacting their daily lives. Consequently, there's a strong demand for novel therapies that can enhance muscle strength and alleviate symptoms, driving the market forward.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭: https://www.alliedmarketresearch.com/request-sample/A11194

The myasthenia gravis treatment market is segmented based on drug class, age group, distribution channel, and region. Intravenous immunoglobulin (IVIg) leads the drug class segment due to its rapid onset, long-lasting effects, and safety profile. Patients above 50 years constitute the largest age group segment, driven by increasing autoimmune disease prevalence.

Drug stores and retail pharmacies dominate distribution channels, while online providers show promising growth due to convenience and improved medication adherence. North America holds the largest market share, while Asia-Pacific is poised for significant growth due to rising autoimmune disease prevalence and increased healthcare investments in emerging economies.

𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐭𝐮𝐝𝐲
By drug class, the intravenous immunoglobulin (IVIg) segment accounted for largest share in terms of revenue for myasthenia gravis treatment industry in 2022.
By age group, the above 50 years segment accounted for largest share in terms of revenue for myasthenia gravis treatment industry in 2022.
On the basis of distribution channel, the drug stores and retail pharmacies segment accounted for largest share in terms of revenue in 2022. However, online providers segment is anticipated to grow at the highest CAGR during the forecast period.
Region wise, North America occupied the largest share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐢𝐧 𝐌𝐲𝐚𝐬𝐭𝐡𝐞𝐧𝐢𝐚 𝐆𝐫𝐚𝐯𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

In September 2022, Ultomiris (ravulizumab) received approval in Europe for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

In April 2023, Global biotechnology leader CSL Behring received the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
Recent Acquisition in Myasthenia Gravis Treatment Market

In April 2022, Grifols a global leader in plasma-derived medicines acquired Tiancheng (Germany) Pharmaceutical Holdings AG, a German company, specialized in innovative hematology and clinical immunology.

In March 2021, Grifols a global healthcare company, acquired GigaGen Inc., a U.S. biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/11559

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the myasthenia gravis medication market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the myasthenia gravis treatment medication market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the myasthenia gravis medication market players.

The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Kedrion SpA
Grifols, S.A.
Zydus Lifesciences Limited
Octapharma AG
AstraZeneca
CSL Limited
Astellas Pharma Inc.
Novartis AG

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/myasthenia-gravis-treatment-market-A11194

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Allied Market Research Blog: https://blog.alliedmarketresearch.com
Follow Us on | Facebook | LinkedIn | YouTube |

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry

This release was published on openPR.